Arrowhead Pharmaceuticals Reports Fiscal Year GAAP EPS and Revenue Miss
Arrowhead Pharmaceuticals (ARWR) reported fiscal year financial results that fell short of market expectations. The company posted a GAAP earnings per share (EPS) of -$5.11, missing analyst estimates by $1.51. Revenue for the period reached $450.82 million, which was $13.32 million below consensus forecasts. This represents a significant year-over-year decline of 45.6%, reflecting substantial contraction in the company's top-line performance.
Tickers: $ARWR
Topics: earnings report EPS miss revenue miss